ANALYSIS OF CONSUMPTION AND COST OF PSYCHOTROPICS FOR FIVE YEARS IN THE MUNICIPALITY OF FOZ DO IGUAÇU – PR

• DOI: https://doi.org/10.22533/at.ed.1594512405066

• Palavras-chave: Psychotropics; Depression; Anxiety; Consumption; Cost.

• Keywords: Psychotropics; Depression; Anxiety; Consumption; Cost.

• Abstract:

  Introduction: The emergence of mental problems such as depression and anxiety has become a serious comorbidity that, if left untreated, generates significant consequences. Among the main classes of psychotropic drugs recommended for the treatment of anxiety and depression are benzodiazepines, inhibitors selective serotonin reuptake drugs (SSRIs) and tricyclic antidepressants (TCAs). Objective: In this sense, the present work sought to answer two guiding questions: what was the consumption of these drugs in the last five years concomitantly with the Covid-19 pandemic and the cost consequences in the region of Foz do Iguaçu – PR. Materials and methods: 

  This is a documentary study, which will be carried out after the consent of the Municipal Health Department of Foz do Iguaçu - PR, where data will be collected from the analysis of annual reports from the last five years (2019 to 2023) provided by the Pharmaceutical Assistance Division (DVFAR) for subsequent analysis and evaluation of the quantity of consumption, individual and collective, together with an economic quantity. Results and discussion: in relation to consumption, the visible curve of Fluoxetine 20 mg with the highest number of units consumed and Clonazepam 2.5 mg/ml with the lowest consumption over five years stands out. Regarding cost, the clearly visible increase in the cost of Clonazepam 2.5 mg/ml drops in relation to other medications and Amitriptyline 25 mg tablets with the lowest average cost stands out. Conclusion: Fluoxetine 20 mg had greater consumption during the 5 years of research, not negatively affecting the costs of acquiring it and that Clonazepam 2.5 mg/ml, when supplied from 2021 in the pharmaceutical form of drops, had a significant impact on costs during the same period.